Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis

被引：9
|
作者：
Sozeri, Betul [1 ]
Kasapcopur, Ozgur [2 ]
机构：
[1] Ege Univ, Fac Med, Dept Pediat, Izmir, Turkey
[2] Istanbul Univ, Cerrahpasa Med Fac, Dept Pediat, Istanbul, Turkey
来源：
CURRENT MEDICINAL CHEMISTRY | 2015年 / 22卷 / 16期
关键词：
Colchicine resistance; Familial Mediterranean fever; therapy; SUBCLINICAL INFLAMMATION; PERIODIC SYNDROME; INTERFERON-ALPHA; TURKISH PATIENTS; DOUBLE-BLIND; CANAKINUMAB; ARTHRITIS; EFFICACY; PROTEIN; TRIAL;
D O I：
10.2174/0929867322666150311152300
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Familial Mediterranean fever (FMF) is the most common hereditary autoinflammatory syndrome. FMF is caused by mutations in the MEFV gene which encodes the pyrin protein. FMF is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1-3 days. Patients may develop renal amyloidosis. Colchicine prevents attacks and renal amyloidosis. 5% to 10% of the patients with FMF are resistant or intolerant to colchicine. Colchicine resistant patients may receive biological therapies. Anti-interleukin-1 drugs are the most important agents of biological treatments. In this review, colchicine resistance and treatment options will be evaluated.
引用
收藏
页码：1986 / 1991
页数：6
相关论文
共 50 条
  • [1] Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments
    Ozen, Seza
    Kone-Paut, Isabelle
    Gul, Ahmet
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 47 (01) : 115 - 120
  • [2] Prevention of Amyloidosis in Familial Mediterranean Fever with Colchicine: A Case-Control Study in Armenia
    Sevoyan, Maria K.
    Sarkisian, Tamara F.
    Beglaryan, Ara A.
    Shahsuvaryan, Gohar R.
    Armenian, Haroutune K.
    MEDICAL PRINCIPLES AND PRACTICE, 2009, 18 (06) : 441 - 446
  • [3] Therapeutic approach to patients with familial Mediterranean fever-related amyloidosis resistant to colchicine
    Korkmaz, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (03) : S104 - S107
  • [4] Early predictors of colchicine resistance in familial Mediterranean fever
    Mosa, Doaa Mosad
    Shokry, Doaa
    Ahmed, Dina B.
    Sobh, Ali
    MODERN RHEUMATOLOGY, 2023, 33 (04) : 830 - 835
  • [5] Treatment of Familial Mediterranean Fever: Colchicine and Beyond
    Gul, Ahmet
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2014, 16 (05): : 281 - 284
  • [6] Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
    El Hasbani, Georges
    Jawad, Ali
    Uthman, Imad
    ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (01)
  • [7] Predictors of AA amyloidosis in familial Mediterranean fever
    Mukhin, Nikolay A.
    Kozlovskaya, Lidiya V.
    Bogdanova, Marina V.
    Rameev, Vilen V.
    Moiseev, Sergey V.
    Simonyan, Armine Kh.
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (07) : 1257 - 1261
  • [8] COLCHICINE PREVENTS KIDNEY-TRANSPLANT AMYLOIDOSIS IN FAMILIAL MEDITERRANEAN FEVER
    LIVNEH, A
    ZEMER, D
    SIEGAL, B
    LAOR, A
    SOHAR, E
    PRAS, M
    NEPHRON, 1992, 60 (04) : 418 - 422
  • [9] Current trends in colchicine treatment in familial Mediterranean fever
    La Regina, M.
    Ben-Chetrit, E.
    Gasparyan, A. Y.
    Livneh, A.
    Ozdogan, H.
    Manna, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (03) : S41 - S46
  • [10] Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
    Omma, Ahmet
    Armagan, Berkan
    Guven, Serdar Can
    Sandikci, Sevinc Can
    Colak, Seda
    Yucel, Cigdem
    Kucuksahin, Orhan
    Erden, Abdulsamet
    FRONTIERS IN PEDIATRICS, 2021, 9
12345